Regulacje i polityka gospodarcza · 29.10.2002

Prospective Grant of Exclusive License: “Modulating IL-13 Activity Using Mutated IL-13 Molecules that are Antagonists or Agonists of IL-13”, PCT Application PCT/US00/31044

This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1) (i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the inventions embodied in PCT application PCT/US00/31044 , entitled "Modulating IL-13 Activity Using Mutated IL-13 Molecules that are Antagonists or Agonists of IL-13", which was filed on November 10, 2000 to NeoPharm, Incorporated which is located in Lake Forest, Illinois. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory will be worldwide and the field of use may be limited to therapy for asthma and other immunological disorders.